SDZ SER-082: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 25: | Line 25: | ||
{{pharma-stub}} | {{pharma-stub}} | ||
{{neuroscience-stub}} | {{neuroscience-stub}} | ||
<gallery> | |||
File:SDZ_SER-082.svg|SDZ_SER-082 | |||
</gallery> | |||
Latest revision as of 23:55, 24 February 2025
SDZ SER-082 is a serotonin receptor antagonist that is used in scientific research. It is a selective antagonist for the 5-HT1A receptor, which is a subtype of the serotonin receptor. SDZ SER-082 is used to study the role of 5-HT1A receptors in various physiological processes and diseases, including anxiety, depression, and schizophrenia.
Pharmacology[edit]
SDZ SER-082 acts by binding to 5-HT1A receptors and blocking their activation by serotonin. This inhibits the effects of serotonin, a neurotransmitter that plays a key role in mood regulation, sleep, and other functions. By selectively blocking 5-HT1A receptors, SDZ SER-082 allows researchers to study the specific role of these receptors in the body.
Uses in Research[edit]
SDZ SER-082 is primarily used in preclinical research. It has been used in studies investigating the role of 5-HT1A receptors in anxiety and depression, as well as in the pathophysiology of schizophrenia. In addition, it has been used to study the effects of 5-HT1A receptor antagonism on sleep and circadian rhythms.
Side Effects[edit]
As a research compound, SDZ SER-082 is not intended for human consumption, and its side effects in humans are not well-studied. However, in animal studies, it has been shown to cause side effects such as decreased locomotor activity and increased body temperature.
See Also[edit]

This article is a neuroscience stub. You can help WikiMD by expanding it!
-
SDZ_SER-082
